BridgeBio Pharma, Inc. (BBIO) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
BBIO's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
BBIO Revenue Analysis (2017–2025)
As of March 2, 2026, BridgeBio Pharma, Inc. (BBIO) generated trailing twelve-month (TTM) revenue of $502.1 million, reflecting explosive growth of +2521.2% year-over-year. The most recent quarter (Q4 2025) recorded $154.2 million in revenue, up 27.7% sequentially.
Looking at the longer-term picture, BBIO's 5-year compound annual growth rate (CAGR) stands at +127.4%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $502.1 million in 2025, representing a new all-time high.
Revenue diversification analysis shows BBIO's business is primarily driven by Product (72%), License and Service (26%), and Royalty (2%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including AGIO (+36.3% YoY), VRTX (+10.4% YoY), and ASND (+97.4% YoY), BBIO has outperformed the peer group in terms of revenue growth. Compare BBIO vs AGIO →
Peer Comparison
Compare BBIO's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BBIOCurrent | $502M | +2521.2% | +127.4% | -113.3% | |
| AGIO | $54M | +36.3% | - | -873.9% | |
| VRTX | $12.0B | +10.4% | +14.1% | 39.1% | |
| ASND | $692M | +97.4% | +150.9% | -18.9% | |
| BMRN | $3.2B | +12.9% | - | 16.6% | |
| PTCT | $1.7B | +97.5% | +35.4% | 50.1% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $502.1M | +126.3% | $473.8M | 94.4% | $-569,087,000 | -113.3% |
| 2024 | $221.9M | +2285.3% | $218.0M | 98.3% | $-592,973,000 | -267.2% |
| 2023 | $9.3M | -88.0% | $6.9M | 73.7% | $-607,370,000 | -6528.8% |
| 2022 | $77.6M | +11.4% | $74.2M | 95.6% | $-512,202,000 | -659.6% |
| 2021 | $69.7M | +745.1% | $66.6M | 95.5% | $-576,632,000 | -827.1% |
| 2020 | $8.2M | -79.7% | $8.2M | 100.0% | $-474,482,000 | -5752.0% |
| 2019 | $40.6M | - | $38.1M | 93.8% | $-266,240,000 | -656.4% |
| 2018 | $0 | - | $0 | - | $-183,660,000 | - |
| 2017 | $0 | - | $-260,000 | - | $-43,858,000 | - |
See BBIO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BBIO Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare BBIO vs AGIO
See how BBIO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is BBIO's revenue growth accelerating or slowing?
BBIO revenue is accelerating at +2521.2% year-over-year, exceeding the 5-year CAGR of +127.4%. TTM revenue reached $502M. Growth momentum has increased versus prior periods.
What is BBIO's long-term revenue growth rate?
BridgeBio Pharma, Inc.'s 5-year revenue CAGR of +127.4% reflects the sustained expansion pattern. Current YoY growth of +2521.2% is above this long-term average.
How is BBIO's revenue distributed by segment?
BBIO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.